Apixaban Prophylaxis for Prevention of Left Ventricular Thrombus Following Anterior Myocardial Infarction

A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 472 participants.

Also called NCT06742567

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; single masking; primary purpose prevention
Phase
Phase 3
Enrolled
  • 472 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT06742567
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Pakistan (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT06742567. Randomized; single masking; primary purpose prevention. Start 2024-12-02 (actual); primary completion 2025-11-30 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Apixaban Prophylaxis for Prevention of Left Ventricular Thrombus Following Anterior Myocardial Infarction
Acronym
POTAMI
Condition
Acute Myocardial Infarction of Anterior Wall
Condition
Left Ventricular Thrombus
Condition
Prophylaxis
Intervention (Drug)
Apixaban 2.5 MG PO BID
Intervention (Drug)
Control (Standard treatment)
Lead sponsor
National Institute of Cardiovascular Diseases, Pakistan (class: other)

Record details

Record id
cardio:ct-nct06742567
Content hash
9c5c34c4a624c8c90b91a78fa796020d31bbc63f314c58765b8245c580771130